← Leaderboards
Bertil E Glader
Stanford University
$2,008,258
Attributed
$2,008,258
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $119.2K · FY2005–10$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$1,769,927 · 6
CDC$238,331 · 1
By mechanism
U01$1,491,900 · 2
M01$278,027 · 4
U58$238,331 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Mark A Kay$46,920,488
- Laurence C Baker$4,100,367
- Jan E Carette$15,833,982
- Michele P Calos$5,346,989
- Mildred K. Cho$21,452,960
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchGene TherapyAdeno Associated Virus GroupClinical Trial Phase ICoagulation Factor IxHemophilia BHuman SubjectHuman Therapy EvaluationTransfection /Expression VectorHemophilia AsHuman DataCooperative StudyData CollectionBiomedical FacilityHealth Science Research Analysis /EvaluationClinical TrialsCoagulation Factor ViiiStriated MusclesTissue Resource /RegistryIntramuscular InjectionsLiverBlood Coagulation DisordersPatient /Disease RegistryPatient Safety /Medical Error
Grant awards (17)
IDENTIFICATION OF PATIENTS WITH DIAMOND BLACKFAN ANEMIA$119,165
U58 · FY2010 · DD · contact PI
IDENTIFICATION OF PATIENTS WITH DIAMOND BLACKFAN ANEMIA$119,166
U58 · FY2009 · DD · contact PI
A PHASE I SAFETY STUDY IN PATIENTS WITH SEVERE HEMOPHILIA B$3,007
M01 · FY2005 · RR
RITUXIMAB FOR CHRONIC, SEVERE IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDREN$334
M01 · FY2005 · RR
Phase I Safety Study in Patients w/ Severe Hemophilia B$5,334
M01 · FY2004 · RR
Hemophilia A &B AAV vector delivery: factors VIII &IX$248,650
U01 · FY2002 · HL
Core--clinical$248,650
U01 · FY2002 · HL
Hemophilia A &B AAV vector delivery: factors VIII &IX$248,650
U01 · FY2001 · HL
Core--clinical$248,650
U01 · FY2001 · HL
UNIVERSAL DATA COLLECTION PROGRAM FOR HEMOPHILIA$134,676
M01 · FY2001 · RR
HEMOPHILIA B GENE THERAPY W/ AAV VECTOR FOR FACTOR IX GE$134,676
M01 · FY2001 · RR
UNIVERSAL DATA COLLECTION PROGRAM FOR HEMOPHILIA$0
M01 · FY2001 · RR
HEMOPHILIA B GENE THERAPY W/ AAV VECTOR FOR FACTOR IX GE$0
M01 · FY2001 · RR
Hemophilia A &B AAV vector delivery: factors VIII &IX$248,650
U01 · FY2000 · HL
Core--clinical$248,650
U01 · FY2000 · HL
HEMOPHILIA B GENE THERAPY W/ AAV VECTOR FOR FACTOR IX GE$0
M01 · FY2000 · RR
UNIVERSAL DATA COLLECTION PROGRAM FOR HEMOPHILIA$0
M01 · FY2000 · RR